Medicines Formulary

Medicines A–Z

O

Drug name	NICE TAs	Comments
Olopatadine (Opatanol®)		Second line - high relative cost.
Omalizumab	TA339 - Omalizumab for previously treated chronic spontaneous urticaria TA278 - Omalizumab for treating severe persistent allergic asthma	Hospital only
Omalizumab	TA339 - Omalizumab for previously treated chronic spontaneous urticaria
Omeprazole capsules
Omeprazole IV		Hospital use only
Omeprazole orodispersible tablets		Second line - for use in swallowing difficulties or via nasogastric tubes.
Ondansetron injection		Red for chemotherapy Amber for hyperemesis in pregnancy (off label) Amber for palliative care (off label) Syrup - swallowing difficulties only
Ondansetron melt tablets		Red for chemotherapy Amber for hyperemesis in pregnancy (off label) Amber for palliative care (off label) Syrup - swallowing difficulties only
Ondansetron SF syrup		Red for chemotherapy Amber for hyperemesis in pregnancy (off label) Amber for palliative care (off label) Syrup - swallowing difficulties only
Ondansetron suppositories		Red for chemotherapy Amber for hyperemesis in pregnancy (off label) Amber for palliative care (off label) Syrup - swallowing difficulties only

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.